Valeritas Holdings, Inc. Presents Positive h-Patch Apomorphine Study Data at the World Congress of Neurology (WCN 2019)
October 29, 2019 at 07:00 am EDT
Share
Valeritas Holdings, Inc. announced that positive data from its preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion was presented on October 29, 2019 at the 24th World Congress of Neurology held in Dubai, UAE. In the poster presentation titled “Delivery of Apomorphine via Subcutaneous Infusion with the h-Patch Wearable Device,” the data demonstrated that 400ul of a 25mg/ml Apo solution delivered with the h-Patch technology was rapidly absorbed and was detected in plasma within two hours of the start of infusion. Additionally, Apo was still detectable in plasma 24 hours after completion of h-Patch infusion, or 48 hours in total. Valeritas proprietary h-Patch device is a simple all-in-one, fully disposable, drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Company’s V-Go is the first FDA-approved product that utilizes its h-Patch technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States. Treatment of advanced Parkinson’s disease (PD) remains challenging, with fluctuations in motor status often resulting in patients becoming severely handicapped. The magnitude and pattern of the motor response to a single dose of subcutaneously administered Apo are qualitatively comparable to that of oral levodopa; however, side effects of oral dosing (dizziness, nausea, vomiting, etc.) can be problematic.
Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.